ORIGINAL ARTICLESEfficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study
-
Add time:09/08/2019 Source:sciencedirect.com
BackgroundAllergic rhinitis afflicts more than 40 million people in the United States and is a leading cause of reduced productivity at work and in school. Patients with allergic rhinitis have a wide range of symptoms that are often treated with oral combination products that contain antihistamines, decongestants, and analgesics.
We also recommend Trading Suppliers and Manufacturers of CLEMASTINE FUMARATE (cas 15686-51-8). Pls Click Website Link as below: cas 15686-51-8 suppliers
Prev:ORIGINAL ARTICLESLow Dose Clemastine Inhibits Sneezing and Rhinorrhea During the Early Nasal Allergic Reaction
Next:Brain energy metabolism is activated after acute and chronic administration of fenproporex (cas 15686-61-0) in young rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- ORIGINAL ARTICLESLow Dose Clemastine Inhibits Sneezing and Rhinorrhea During the Early Nasal Allergic Reaction09/07/2019
- Original articleClemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel09/06/2019
- High-performance liquid chromatographic-tandem mass spectrometric method for the determination of clemastine in human plasma09/05/2019
- Development and full validation of a sensitive quantitative assay for the determination of clemastine in human plasma by liquid chromatography–tandem mass spectrometry09/04/2019
- Short communicationDetermination of clemastine in human plasma by gas chromatography with nitrogen–phosphorus detection09/03/2019
- Original articleDetermination of clemastine hydrogen fumarate, desloratadine, losartan potassium and moxepril HCl through binary complex formation with eosin09/02/2019
- ArticlesCLEMASTINE FUMARATE (cas 15686-51-8) as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial09/01/2019


